1. Real-World Evidence in VTE

2. Program Goals

3. Overview

4. Khorana Risk Score Calculator

5. CATCH Trial

6. CATCH Trial: Results

7. CATCH Biomarker Analysis TF

8. VTE Recurrence Among Rivaroxaban-Treated Patients Who Continued vs Discontinued Therapy

9. Major Bleeding After Initial 3 Months of Therapy

10. Major Bleeding Among Patients With and Without Cancer Taking Rivaroxaban: A DoD Cohort Analysis

11. Healthcare Resource Utilization Associated With VTE Recurrence in Cancer

12. Healthcare Costs Associated With VTE Recurrence in Cancer

13. AVERT and CASSINI Trial Designs

14. VTE Prophylaxis

15. Real-World Evidence: XALIA

16. XALIA Results

17. XALIA Results (cont)

18. XALIA: Patients With Cancer

19. XALIA: Cancer Substudy Primary Outcomes

20. Some Studies of NOACs in Cancer

21. Abbreviations

22. Abbreviations (cont)